靶向肿瘤转移的新策略

国际肿瘤学杂志››2025,Vol. 52››Issue (8): 528-531.doi:10.3760/cma.j.cn371439-20240811-00089

张百红¹, 岳红云²()

¹解放军联勤保障部队第九四〇医院肿瘤科，兰州 730050
²解放军联勤保障部队第九四〇医院眼科，兰州 730050

收稿日期:2024-08-11修回日期:2024-09-10出版日期:2025-08-08发布日期:2025-09-15
通讯作者:岳红云 E-mail:yhyophthalmologist@163.com
基金资助:
甘肃省自然科学基金(22JR5RA007)

Novel therapeutic strategies： targeting cancer metastasis

Zhang Baihong¹, Yue Hongyun²()

¹Department of Oncology， 940th Hospital of Joint Logistics Support Force of People's Liberation Army， Lanzhou 730050， China
²Department of Ophthalmology， 940th Hospital of Joint Logistics Support Force of People's Liberation Army， Lanzhou 730050， China

Received:2024-08-11Revised:2024-09-10Online:2025-08-08Published:2025-09-15
Contact:Yue Hongyun E-mail:yhyophthalmologist@163.com
Supported by:
Natural Science Foundation of Gansu Province of China(22JR5RA007)

摘要/Abstract

摘要：

肿瘤相关死亡往往与肿瘤转移相关。转移过程包括肿瘤细胞获得播散特质、休眠苏醒和远处生长。改变细胞播散特质、维持和杀灭休眠细胞、编辑转移前微环境和重构肿瘤特征可能阻断肿瘤转移。贝伐珠单抗、地舒单抗和西仑吉肽等药物已经应用于临床。基于血液检查的肿瘤筛查联合人工智能将为临床治疗肿瘤提供新的靶向转移策略。

关键词:肿瘤,肿瘤转移,治疗

Abstract:

Tumor-related death is often associated with tumor metastasis. Metastasis process includes the acquisition of dissemination traits of tumor cells， dormancy awakening， and distant growth. Changing dissemination traits of cancer cells， maintaining and killing dormant tumor cells， editing pre-metastatic microenvironment， and reprogramming hallmarks of cancer will be key to block tumor metastasis. Bevacizumab， denosumab and cilengitide have been approved for clinical therapies. Tumor screening based on blood tests combined with artificial intelligence will provide new targeted metastasis strategies for clinical treatment.

Key words:Neoplasms,Neoplasm metastasis,Therapeutics

张百红, 岳红云. 靶向肿瘤转移的新策略[J]. 国际肿瘤学杂志, 2025, 52(8): 528-531.

Zhang Baihong, Yue Hongyun. Novel therapeutic strategies： targeting cancer metastasis[J]. Journal of International Oncology, 2025, 52(8): 528-531.

参考文献36

[1]	Gerstberger S, Jiang Q, Ganesh K. Metastasis[J].Cell,2023,186(8): 1564-1579. DOI:10.1016/j.cell.2023.03.003. pmid:37059065
[2]	Ganesh K, Massagué J. Targeting metastatic cancer[J].Nat Med,2021,27(1): 34-44. DOI:10.1038/s41591-020-01195-4. pmid:33442008
[3]	Ganesh K. Uncoupling metastasis from tumorigenesis[J].N Engl J Med,2023,388(7): 657-659. DOI:10.1056/NEJMcibr2213497.
[4]	Coban B, Bergonzini C, Zweemer AJM, et al. Metastasis: crosstalk between tissue mechanics and tumour cell plasticity[J].Br J Cancer,2021,124(1): 49-57. DOI:10.1038/s41416-020-01150-7.
[5]	Pérez-González A, Bévant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy[J].Nat Cancer,2023,4(8): 1063-1082. DOI:10.1038/s43018-023-00595-y.
[6]	Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy[J].Nat Rev Drug Discov,2020,19(1): 39-56. DOI:10.1038/s41573-019-0044-1. pmid:31601994
[7]	Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer[J].Science,2023,379(6632): eaaw3835. DOI:10.1126/science.aaw3835.
[8]	Crunkhorn S. Blocking breast cancer metastasis[J].Nat Rev Drug Discov,2022,21(3): 180. DOI:10.1038/d41573-022-00026-0.
[9]	Nair PR, Danilova L, Gómez-de-Mariscal E, et al. MLL1 regulates cytokine-driven cell migration and metastasis[J].Sci Adv,2024,10(11): eadk0785. DOI:10.1126/sciadv.adk0785.
[10]	Richbourg NR, Irakoze N, Kim H, et al. Outlook and opportunities for engineered environments of breast cancer dormancy[J].Sci Adv,2024,10(10): eadl0165. DOI:10.1126/sciadv.adl0165.
[11]	Correia AL. Locally sourced: site-specific immune barriers to metastasis[J].Nat Rev Immunol,2023,23(8): 522-538. DOI:10.1038/s41577-023-00836-2. pmid:36750616
[12]	Xia F, Ma Y, Chen K. Genome-wide in vivo screen of circulating tumor cells identifies SLIT2 as a regulator of metastasis[J].Sci Adv,2022,8(35): eabo7792. DOI:10.1126/sciadv.abo7792.
[13]	Baek AE. Metastatic dormancy needs STING[J].Sci Signal,2023,16(780): eadi1372. DOI:10.1126/scisignal.adi1372.
[14]	Micalizzi DS, Che D, Nicholson BT, et al. Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody[J].Proc Natl Acad Sci U S A,2022,119(43): e2209563119. DOI:10.1073/pnas.2209563119.
[15]	Gkountela S, Castro-Giner F, Szczerba BM, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding[J].Cell,2019,176(1/2): 98-112.e14. DOI:10.1016/j.cell.2018.11.046.
[16]	Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer[J].Cell,2022,185(8): 1356-1372.e26. DOI:10.1016/j.cell.2022.02.027. pmid:35395179
[17]	Zhang F, Guo Z, Li Z, et al. Biohybrid microrobots locally and actively deliver drug-loaded nanoparticles to inhibit the progression of lung metastasis[J].Sci Adv,2024,10(24): eadn6157. DOI:10.1126/sciadv.adn6157.
[18]	Yu Y, Cheng Q, Ji X, et al. Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis[J].Sci Adv,2022,8(49): eadd3599. DOI:10.1126/sciadv.add3599.
[19]	Kaczanowska S, Kaplan RN. Mapping the switch that drives the pre-metastatic niche[J].Nat Cancer,2020,1(6): 577-579. DOI:10. 1038/s43018-020-0076-9.
[20]	Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions[J].Cell,2023,186(8): 1652-1669. DOI:10.1016/j.cell.2023.03.006. pmid:37059068
[21]	Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation—have anti-inflammatory therapies come of age?[J].Nat Rev Clin Oncol,2021,18(5): 261-279. DOI:10.1038/s41571-020-00459-9.
[22]	Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond[J].Nat Rev Drug Discov,2023,22(6): 476-495. DOI:10.1038/s41573-023-00671-z.
[23]	Hofbauer LC, Bozec A, Rauner M, et al. Novel approaches to target the microenvironment of bone metastasis[J].Nat Rev Clin Oncol,2021,18(8): 488-505. DOI:10.1038/s41571-021-00499-9. pmid:33875860
[24]	Liu F, Wu Q, Dong Z, et al. Integrins in cancer: emerging mechanisms and therapeutic opportunities[J].Pharmacol Ther,2023,247: 108458. DOI:10.1016/j.pharmthera.2023.108458.
[25]	Whiteley AE, Ma D, Wang L, et al. Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis[J].Science,2024,384(6702): eadh5548. DOI:10.1126/science.adh5548.
[26]	Weiss F, Lauffenburger D, Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance[J].Nat Rev Cancer,2022,22(3): 157-173. DOI:10.1038/s41568-021-00427-0. pmid:35013601
[27]	Demicco M, Liu XZ, Leithner K, et al. Metabolic heterogeneity in cancer[J].Nat Metab,2024,6(1): 18-38. DOI:10.1038/s42255-023-00963-z. pmid:38267631
[28]	Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis[J].Nat Cancer,2024,5(1): 16-29. DOI:10.1038/s43018-023-00702-z.
[29]	Battaglia TW, Mimpen IL, Traets JJH, et al. A pan-cancer analysis of the microbiome in metastatic cancer[J].Cell,2024,187(9): 2324-2335. DOI:10.1016/j.cell.2024.03.021. pmid:38599211
[30]	Wang Y, Narasimamurthy R, Qu M, et al. Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis[J].Nat Cancer,2024,5(4): 546-556. DOI:10.1038/s43018-024-00759-4.
[31]	Zahalka AH, Frenette PS. Nerves in cancer[J].Nat Rev Cancer,2020,20(3): 143-157. DOI:10.1038/s41568-019-0237-2. pmid:31974491
[32]	Cambria E, Coughlin MF, Floryan MA, et al. Linking cell mechanical memory and cancer metastasis[J].Nat Rev Cancer,2024,24(3): 216-228. DOI:10.1038/s41568-023-00656-5. pmid:38238471
[33]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J].国际肿瘤学杂志,2024,51(6): 354-358. DOI:10.3760/cma.j.cn371439-20240318-00061.
[34]	Ho D. Artificial intelligence in cancer therapy[J].Science,2020,367(6481): 982-983. DOI:10.1126/science.aaz3023. pmid:32108102
[35]	Pan C, Schoppe O, Parra-Damas A, et al. Deep learning reveals cancer metastasis and therapeutic antibody targeting in the entire body[J].Cell,2019,179(7): 1661-1676.e19. DOI:10.1016/j.cell.2019.11.013. pmid:31835038
[36]	Micalizzi DS, Sequist LV, Haber DA. Deploying blood-based cancer screening[J].Science,2024,383(6681): 368-370. DOI:10.1126/science.adk1213. pmid:38271495